

16 July 2025

**Scancell Holdings plc**  
("Scancell" or the "Company")

**Share Option Exercise**

**Scancell Holdings plc (AIM: SCLP)**, the developer of novel immunotherapy products for the treatment of multiple cancers, announces that it has received notice from a former employee of the Company to exercise options over 1,000,000 ordinary shares of 0.1 pence each in the Company ("**Ordinary Shares**") at an exercise price of 8.15 pence per share.

An application has been made to London Stock Exchange plc for the new Ordinary Shares to be admitted to trading on AIM ("**Admission**"). It is expected that Admission will become effective and dealings commence at 8.00 a.m. on or around, 21 July 2025. The new Ordinary Shares will rank *pari passu* with the existing ordinary shares of the Company.

**Total Voting Rights**

Following Admission, the total number of ordinary shares in issue will be 1,037,781,403. The Company does not hold any ordinary shares in treasury. Therefore, the total number of ordinary shares with voting rights will be 1,037,781,403. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

*For more information please contact:*

<b>Scancell Holdings plc</b> Phil L'Huillier, CEO Sath Nirmalanathan, CFO	+44 (0) 20 3709 5700
<b>Panmure Liberum</b> (Nominated Adviser and Joint Broker) Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking)	+44 (0) 20 7886 2500
<b>WG Partners LLP (Joint Broker)</b> David Wilson, Claes Spang	+44 (0) 20 3705 9330
<b>Investor and media relations</b> Mary-Ann Chang	+44 (0) 20 7483 284853 MaryAnnChang@scancell.co.uk

**Scancell (LSE:SCLP; [www.scancell.co.uk](http://www.scancell.co.uk))** is a clinical stage biotechnology company developing targeted off-the-shelf immunotherapies which enhance long-lasting tumour specific immunity for a cancer-free future. Scancell's lead product, iSCIB1+ immunotherapy, has shown strong promise, showing clinically meaningful additional benefit when combined with checkpoint therapies. The second immunotherapy, Modi-1, is being investigated in a phase 2 study in a broad

range of solid tumours. Scancell also has an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans. Two GlyMab® antibodies are being developed by Genmab under license from Scancell.